clinical / clinicalPancreatic Cancer

Matthew H.G. Katz

马修·卡茨

🏢The University of Texas MD Anderson Cancer Center(德克萨斯大学MD安德森癌症中心)🌐USA

Professor and Deputy Chair, Department of Surgical Oncology外科肿瘤学系教授兼副主任

h-index

Key Papers

Awards

Key Contributions

👥Biography 个人简介

Dr. Katz is an internationally recognized surgical oncologist who established the concept of borderline resectable pancreatic cancer and pioneered neoadjuvant therapy protocols that have transformed surgical outcomes in PDAC. He leads multidisciplinary care and training programs at MD Anderson.

🧪Research Fields 研究领域

Borderline Resectable Pancreatic Cancer交界可切除胰腺癌

Neoadjuvant Therapy新辅助治疗

Pancreatic Surgery胰腺外科

Surgical Oncology外科肿瘤学

Pancreatectomy胰腺切除术

Multimodal Treatment多模式治疗

🎓Key Contributions 主要贡献

Borderline Resectable PDAC

Defined and standardized the classification of borderline resectable pancreatic cancer, enabling stratified treatment approaches and improving patient selection for surgery with curative intent.

Neoadjuvant Therapy Protocols

Pioneered neoadjuvant chemotherapy and chemoradiation protocols for locally advanced and borderline resectable PDAC, significantly increasing R0 resection rates and overall survival.

Representative Works 代表性著作

[1]

Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

Annals of Surgical Oncology (2016)

Foundational review defining borderline resectable PDAC classifications and evidence-based neoadjuvant strategies.

[2]

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation for Borderline Resectable PDAC

Journal of Clinical Oncology (2022)

Phase II trial evaluating preoperative regimens in borderline resectable disease, informing current treatment standards.

🏆Awards & Recognition 奖项与荣誉

🏆Society of Surgical Oncology Award for Excellence

🏆MD Anderson Department of Surgical Oncology Outstanding Faculty Award

🏆American Hepato-Pancreato-Biliary Association Distinguished Service Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Hope S. Rugo

University of California, San Francisco (UCSF)

Antibody-Drug Conjugates in Metastatic Breast CancerASCENT Trial and Sacituzumab Govitecan

Maryam B. Lustberg

Yale School of Medicine / Yale Cancer Center

Cardiotoxicity of CDK4/6 Inhibitors and Endocrine TherapyCancer Treatment-Related Cardiovascular Disease

Sara M. Tolaney

Dana-Farber Cancer Institute / Harvard Medical School

T-DM1 and KATHERINE Trial in Residual Disease After Neoadjuvant TherapyTrastuzumab Deruxtecan (T-DXd) and DESTINY-Breast Trials

Carlos H. Barrios

PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil

CDK4/6 Inhibitors in Low- and Middle-Income Countries (LMIC)Global Breast Cancer Clinical Trials and Access

关注马修·卡茨的研究动态

Follow Matthew H.G. Katz's research updates

留下邮箱，当我们发布与 Matthew H.G. Katz（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All Experts Read Research Insights

International Translational Oncology Exchange